Pharma major Lupin announced on Wednesday that its subsidiary Lupin Pharmaceuticals has received final approval for its Irbesartan tablets from the US Food and Drugs Administration (FDA). It can now market a generic version of Sanofi Aventis’s Avapro tablets. Irbesartan tablets are used for treating hypertension and nephropathy in type 2 diabetic patients and are available in 75 mg 150 mg and 300 mg strength. According to the IMS health sales data Avapro tablets had annual US sales of about $400.7 million in June. With 5.1% market share by prescriptions Lupin is the fifth largest generic player in the US.